Mutational analysis of oncogenes is critical for our understanding of cancer development. Oncogenome screening has identified a fibroblast growth factor receptor 4 (FGFR4) Y367C mutation in the human breast cancer cell line MDA-MB453. Here, we investigate the consequence of this missense mutation in cancer cells. We show that MDA-MB453 cells harbouring the mutation are insensitive to FGFR4-specific ligand stimulation or inhibition with an antagonistic antibody. Furthermore, the FGFR4 mutant elicits constitutive phosphorylation leading to an activation of the mitogen-activated protein kinase cascade as shown by an enhanced Erk1/2 phosphorylation. Cloning and ectopic expression of the FGFR4 Y367C mutant in HEK293 cells revealed high pErk levels and enhanced cell proliferation. Based on these findings, we propose that FGFR4 may be a driver of tumour growth, particularly when highly expressed or stabilized and constitutively activated through genetic alterations. As such, FGFR4 presents an option for further mutational screening in tumours and is an attractive cancer target with the therapeutic potential.
Introduction
Activation of oncogenes is a key mechanism for driving tumourigenesis and cancer progression. Such activation often arises from genetic alterations, either by mutation or by amplification of genes that have a pivotal role in the maintenance of cellular homeostasis. As such, genome-wide screening has been used extensively for the discovery of novel mutations in cell signalling molecules such as the tyrosine kinase superfamily to better understand the pathophysiology of cancers and to identify new drug targets (Bardelli et al., 2003; Stephens et al., 2004 Stephens et al., , 2005 Bignell et al., 2006; Greenman et al., 2007; Ruhe et al., 2007; Thomas et al., 2007) . However, a major constraint in this process is the difficulty in establishing the functional significance of newly discovered genetic lesions for cancer formation and progression.
Owing to their involvement in cellular signalling pathways, mutations of kinases, especially receptor tyrosine kinases, are known to have major pathological consequences. In the FGF receptor subfamily, various mutations are identified to have a dominant role in the development of diverse diseases such as bone development disorders (Apert's, Pfeiffer's, Beare-Stevenson, SADDAN syndrome and achondroplasia) (Wilkie, 2005) and cancer (Eswarakumar et al., 2005) . The four members of the human fibroblast growth factor receptors (FGFR 1-4) belong to the receptor tyrosine kinase family and consist of three extracellular immunoglobulin domains, an acidic box, except for FGFR2, a HAV motif (histidine-alanine-valine) and a split tyrosine kinase domain (Eswarakumar et al., 2005) . Currently 22 ligands are known to activate FGF receptors and stimulate a multitude of signalling pathways (Itoh and Ornitz, 2004) . On ligand binding, FGFRs become trans-phosphorylated, which results in the recruitment of the central adaptor protein FGFR substrate 2 (FRS2) and subsequent downstream signalling. FGFR signalling leads among other effects to activation of mitogen-activated protein kinase (MAPK) in breast cancer cells and thereby stimulates proliferation (Shaoul et al., 1995; Koziczak et al., 2004) . Other cellular properties such as differentiation, motility (Dailey et al., 2005) and invasiveness (Bange et al., 2002) are also regulated by FGFRs. Importantly, FGFRs have been reported to contribute to oncogenic cell transformation in different human cancers (Yamaguchi et al., 1994; Giri et al., 1999) . We have recently shown that FGFR4 overexpression is associated with chemoresistance in cancer cells and that inhibition of FGFR4 reverses resistance and leads to increased chemosensitivity (Roidl et al., 2009) . Furthermore, we identified a single-nucleotide polymorphism in the transmembrane domain of the FGFR4 resulting in a codon conversion from glycine to arginine (G388R), which is homologous to that in FGFR3 causing achondroplasia (Bange et al., 2002) . This single-nucleotide polymorphism (SNP) is associated with increased cell motility in vitro as well as lymph node metastasis, advanced tumour stage, resistance to adjuvant therapy and therefore leading to reduced survival of cancer patients (Bange et al., 2002; Thussbas et al., 2006) . These findings indicate an important role of FGFR4 in tumour biology.
Recently, Ruhe et al. (2007) discovered a Y367C mutation in the FGFR4 gene by a comprehensive analysis of the tyrosine kinase gene family in cancer cell lines. This mutation occurred in the breast cancer cell line MDA-MB453. As reported previously, MDA-MB453 breast cancer cells overexpress FGFR4 in response to doxorubicin treatment to escape druginduced cell death. We revealed that an antagonistic FGFR4 antibody could not sensitise MDA-MB453 cells to chemotherapeutic drug treatment in contrast to other FGFR4-overexpressing cell lines (Roidl et al., 2009) . As FGFR4 is involved in conferring cancer characteristic properties such as uncontrolled proliferation, invasiveness and motility, as well as anti-apoptosis and chemoresistance, we have further analysed the molecular effects of this mutation in cancer cells.
In this report, we show that the Y367C mutation of FGFR4 causes spontaneous dimerization, thus rendering it constitutively active and independent of ligand stimulation. This phenotype apparently drives tumour growth in MDA-MB453 cells, in which FGFR4 is the predominant member of the FGFR family, and makes the tumour cells independent of any other oncogenic influence. Hence, our findings implicate FGFR4 as a critical factor for oncogenic transformation, particularly when FGFR4 is overexpressed or harbours activating mutations such as Y367C. This underscores the potential of FGFR4 mutational screening, as well as the exploitation of FGFR4 as a drug target for cancer therapy development.
Results

MDA-MB453 breast cancer cells harbour the Y367C FGFR4 mutation
To further characterize the tyrosine-to-cysteine missense mutation at position 367 of the FGFR4, which we found previously in MDA-MB453 (Ruhe et al., 2007) , we sequenced FGFR4 in both MDA-MB453 cDNA and genomic DNA. Homozygous expression of the mutant allele was observed in cDNA, even though heterozygosity was found at the genomic DNA level (Figures 1a  and b) . This shows an allele-specific expression for the mutant allele, drawing more interest for its further investigation.
A search for published homologous mutations in other FGFRs affecting the extracellular juxtamembrane tyrosine of the receptor revealed a Y375C mutation of FGFR2 (Vargas et al., 2003) and a Y373C mutation of FGFR3 (Rousseau et al., 1996) . Both of these mutations resulted in an increased FGFR signalling. Importantly, studies have also linked them to various human syndromes (Figure 1c) : the Y373C mutation of FGFR3 causes SADDAN disease, a severe form of dwarfism, and the Y375C mutation of FGFR2 causes the BeareStevenson syndrome. Many of the characteristic features of these syndromes derive from the premature fusion of the skull bones. However, the homologous mutation in FGFR4 Y367C has not yet been described as being connected to any pathological disorder.
In MDA-MB453 cells FGFR4 is the predominant FGFR family member and exhibits the highest mRNA expression of 318 cell lines The relevance of this mutant genotype to any disease state requires it to be expressed in the first place. To evaluate the abundance of the mutated FGFR4, we analysed the expression of other FGFR family members in the breast cancer cell line MDA-MB453. FGFR4 was found to be the most abundant FGFR, with transcript level more than 80-fold higher than the next most abundant, namely FGFR1, FGFR3 and FGFR2 (Figure 2a) . To compare FGFR4 expression levels in different cell lines, we analysed 16 breast cancer cell lines available in our cell bank by western blotting (Supplementary Figure S1 ). MDA-MB453 cells showed the highest FGFR4 expression in this panel. The expression is even higher than that for HuH7 (the strongest expressor among the NCI-60 panel of cancer cell lines), for which linkage to tumour proliferation has already been described (Ho et al., 2009 ). In addition, we scrutinised a study by Wooster et al., in the Oncomine (Compendia Bioscience, Ann Arbor, MI, USA) database (Rhodes et al., 2004) , in which the gene expression of different cell lines was determined. Of 318 cell lines analysed, MDA-MB453 cells showed by far the highest FGFR4 gene expression (Figure 2b ), compounding the unique feature of the Y367C mutation in this cell line.
MDA-MB453 cells show enhanced FGFR4 signalling
We then investigated the effects of mutation to FGFR4 signalling. Cysteine residues in close proximity are known to form inter-or intra-molecular disulfide bonds connecting protein chains. Therefore, we hypothesized that spontaneous FGFR4 dimerization between FGFR4 monomers may occur on the cell surface of MDA-MB 453 cells, thereby activating and stabilizing the signalling competent receptor form. Thus, we performed native gel electrophoresis and determined the occurrence of FGFR4 dimers in MDA-MB453 breast cancer cells. We observed a high molecular weight band at approximately 180 kDa in MDA-MB453 cells, suggesting the formation of FGFR4 dimers. In contrast, MDA-MB361 cells carrying wild-type (WT) FGFR4 and similar protein level (Supplementary Figure S1) did not show any evidence of a similar high molecular weight band in addition to the 93-kDa monomer band (Figure 3a) . FGFR4-Y367C signalling was inhibited by small interfering RNA but was resistant to an antagonistic antibody Next we examined the phenotypic effects on silencing FGFR4 Y367C signalling. Transient small interfering RNA (siRNA) knockdown produced a 50% reduction in protein levels in two of the constructs, siRNA-14 and siRNA-15 (Supplementary Figure S3) . Consequently, MAPK signalling was diminished, as shown by the reduced Erk phosphorylation (Figure 5a) .
Surprisingly, stable transfection of MDA-MB453 cells with a vector generating FGFR4-specific siRNA yielded no cells with reduced FGFR4 expression (data not shown) in contrast to other cell lines for which stable FGFR4 knockdown could be achieved (Roidl et al., 2009) Subsequently, MDA-MB453 and MDA-MB361 cells were treated with an FGFR4 antagonistic antibody to characterize the potential of FGFR4 as a therapeutic target. This 10F10 monoclonal antibody was raised against the extracellular domain of FGFR4 and was shown to inhibit FGFR4 signalling (Roidl et al., 2009 ). Although we observed no effect in the cell line harbouring the Y367C mutation, Erk phosphorylation in MDA-MB361 cells treated with the 10F10 antibody was clearly inhibited (Figure 5d ).
Ectopic expression of the Y367C mutation of FGFR4 in HEK293 cells leads to enhanced Erk activation and proliferation To further analyse the effect of the FGFR4 Y367C mutation on cellular signalling, we cloned the mutant and the WT receptor and ectopically expressed the constructs in HEK293 cells (low basal FGFR4 WT expression). As expected, overexpression of FGFR4 WT revealed elevated pErk levels. More importantly, cells overexpressing FGFR4 Y367C further enhanced pErk levels, indicating a constitutively active MAPK cascade. This suggests Y367C to be a potent activating mutation of the FGFR4 (Figure 6a ). Interestingly, Akt and pAkt levels were not detectably influenced by overexpression of the Y367C mutant (Supplementary Figure S4) .
Next we investigated whether the effect on Erk phosphorylation is translated to physiological consequences in HEK293 cells. Proliferation was measured by counting the cell number. Here, cells overexpressing the FGFR4 Y367C variant have the proliferation rate doubled, whereas WT FGFR4 overexpression only slightly enhanced the proliferation (about 25%) compared with control cells (Figure 6b ). Separately, we performed a scratch-wound assay to investigate the effect of mutation on cell migration. Our results revealed no significant difference in the percentage of migrating cells between the constructs (Figures 6c and d) . However, the effect of enhanced proliferation is also reflected in this assay in which wound closure is enhanced, underscoring the proliferative effect of the FGFR4 Y367C variant.
Although FGFR4 WT or known mutants have never been associated with any cell transformation ability, FGFR4 Y367C mutation A Roidl et al we evaluated this potential by performing focus formation assay on NIH3T3 cells. Our results showed no effect on cell transformation by either the WT or the Y367C construct. On the other hand, SRC oncogene was able to induce significant colony formation at 21-day incubation (Supplementary Figure S5) .
Discussion
The advent of high-throughput genome-wide sequencing in primary tumours or cancer cell lines has led to the identification of hundreds of mutations. However, these approaches commonly lacked adequate follow-ups to elucidate the functional consequences of the obtained changes. As diagnostic, prognostic or therapeutic value of the genetic alterations depends heavily on the clinical relevance of this information, proving their direct involvement in both tumour formation and progression becomes a task of paramount importance. Therefore, we investigated functional evidence for the enhanced tumour growth of the Y367C mutation of FGFR4, which we recently discovered (Ruhe et al., 2007) . We hypothesized that this genetic alteration can lead to a constitutively active receptor tyrosine kinase and thus enhanced tumour growth. The basis for this postulation capitalized on the proven effect that a juxtamembrane tyrosine-to-cysteine mutation predisposes disulphide bond formation between adjacent cysteine residues. We assumed that mutated FGFR4 monomers, clustering on the cell surface, could increase the incidence of dimer formation, thereby catalysing transactivation of the tyrosine kinase domain to trigger downstream signalling.
Accordingly, we detected a high molecular weight band representing FGFR4 dimers in a native gel electrophoresis that was absent in the corresponding WT FGFR4. The association of the two FGFR4 monomers positions their tyrosine kinase domains in close proximity and results in trans-phosphorylation FGFR4 Y367C mutation A Roidl et al of tyrosine residues. Consequently, this results in the recruitment of adaptor proteins such as FRS2. FRS2 then serves as a binding platform for various adaptor proteins, such as gab1, shc, grb2, and other signalling molecules (Eswarakumar et al., 2005) that mediate further downstream signalling. Here, we found the Y367C mutated FGFR4 to exhibit elevated autophosphorylation as compared with the WT FGFR4, and also showed a constitutively active downstream MAPK cascade. In fact, Erk phosphorylation was slightly elevated under serum-starved conditions, which could be due to an inactivation of phosphatases while maintaining a high FGFR4 kinase activity. This results in a high proliferative potential that leads to enhanced tumour growth. Other effects on different properties of FGFR4 signalling, such as interfering with chemosensitivity or invasion and migration, remain to be elucidated. Taken together, it can be deduced that the unique Y367C mutation found in MDA-MB453 contributes to the high level of FGFR4 activity through dimerization and constitutive phosphorylation, which then confers the dominant signal to drive tumour behaviour in this cell line.
Recent studies have shown an increasing significance of deregulated FGFR4 in terms of tumour progression of different cancers. In many studies the allelic distribution of FGFR4-Gly388 or FGFR4-Arg388 has prognostic values for disease progression, such as in prostate, breast, and head and neck carcinomas (Streit et al., 2004 Ma et al., 2008; Sasaki et al., 2008) . Biochemically, this polymorphism influences protein stability and dysregulates FGFR4 signalling at the post-transcriptional level (Wang et al., 2008) . Furthermore, expressions of certain polymorphisms or mutations have an impact on the chemosensitivity of tumours (Thussbas et al., 2006; Ansell et al., 2009) . Thus, the identification of the Y367C and its consequence of an increased FGFR4 signalling provide an additional mechanism of FGFR4 perturbation that supports tumourigenic activities and hence its value as a potential drug target.
However, the question whether one single mutation can drive tumour growth lingers in the context of this study (Weinstein, 2002) . MDA-MB453 cells seem to become addicted to constitutive FGFR4 signalling, given that a complete knockdown of FGFR4 by stable selection produced no surviving clones (data not shown). However, in other knockdown experiments in various cell lines containing the WT receptor, we could efficiently knock down FGFR4 expression (Roidl et al., 2009) . Moreover, the exceptional behaviour of MDA-MB453 cell line can be seen by the study of Wooster et al., in which the gene expression in 318 cell lines was deposited and analysed in the Oncomine database ( Rhodes et al., 2004) . In that study, the highest FGFR4 expression of all cell lines could be detected in MDA-MB453 cells. This uniquely high level underscored the role of Y367C in maintaining a strong mitogenic signal of FGFR4, and the lethality of its knockdown further implied its essential role in sustaining tumourigenicity in MDA-MB453.
A substitution of tyrosine with cysteine in the extracellular juxtamembrane domain is highly conserved throughout the FGFR family. Importantly, homologous mutations in FGFR1 (Y372C), FGFR2 (Y375C) and FGFR3 (Y373C) were identified and cause various osteogenic deficiency syndromes (Wilkie, 2005) . It was shown that FGFR1 Y372C (White et al., 2005) and FGFR3 Y373C (d 'Avis et al., 1998) are constitutively activated in vitro. For the FGFR3 Y373C mutation, the oncogenic potential was shown and it was suggested that this mutation contributes to the tumour progression of multiple myeloma (Chesi et al., 2001) . In addition to substitutions of tyrosine-to-cysteine in FGFRs, similar mutations occur in other receptor tyrosine kinases, indicating a general mechanism for constitutive oncogenic signalling. For example, the Y606C mutation of the oncogene RET, identified in a medullary thyroid carcinoma, leads to increased receptor dimerization and thus constitutive receptor activation (Ercolino et al., 2008) . Consequently, such mutations achieve one of the hallmarks of cancer, the self-sufficiency in growth factors. Hence, we hypothesize that the mutated juxtamembrane cysteine residue in FGFR4 is yet another conserved but novel activating mutation for this receptor tyrosine kinase subfamily. It facilitates disulphide bond formation, thereby preclustering the kinases, and leads to ligand-independent, uncontrollable activation of signalling pathways. The ligand independence of the mutant was confirmed by the inability of the extracellular domain binding antibody to downregulate FGFR4 signalling in MDA-MB453 cells, a phenomenon not seen with WT FGFR4 (BT474, MDA-MB361 and ZR575-1) as performed by our group previously (Roidl et al., 2009) . On the contrary, reducing total FGFR4 protein expression by siRNA was still sufficient to inhibit signalling. Therefore, designing a small-molecule inhibitor that binds to the intracellular kinase domain instead of the ligandbinding domain might present a more attractive therapeutic intervention in this context. Although it can be argued that this activating mutation in FGFR4 is a rare event, the consequences of the high FGFR4 activity caused by the mutation extend the clinical relevance of this finding to all tumours in which high FGFR4 activity or expression is manifested. Such high expression is shown in this report in a representative panel of breast carcinoma cell lines (Supplementary Figure S1) , as well as previously in a subset of Asian hepatocellular carcinoma patients (Ho et al., 2009 ).
In conclusion, we have shown through FGFR4-Y367C that a genetic alteration identified from a mutational screen can guide a purposeful investigation to establish the biochemical link of the mutation to an oncogenic phenotype. Further analysis of the direct involvement of mutations in tumour progression will show new molecular anticancer targets, such as FGFR4, which can then be exploited for novel therapeutic approaches. In addition, mutational screening of patient tumour samples will confirm these findings and pave the way to new and sophisticated drugs. These efforts will get us closer towards a personalized cancer therapy.
Materials and methods
Reagents and antibodies FGF19 ligand was purchased from TEBU (Offenbach, Germany). The antibodies used were polyclonal anti-FGFR4, anti-Erk1/2, anti-HSP60 and anti-Akt1/2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal antiphospho-Akt (Ser473) (New England BioLabs, Beverly, MA, USA), mouse monoclonal anti-phosphotyrosine antibody 4G10 (Upstate Biotechnology, Lake Placid, NY, USA), rabbit polyclonal anti-phospho-Erk (Cell Signalling, Danvers, MA, USA) and mouse monoclonal anti-FGFR4 antibody 10F10 (U3 Pharma, Martinsried, Germany). The monoclonal antibody 10F10 was raised against the purified extracellular domain of FGFR4.
Secondary HRP-conjugated antibodies were goat antimouse (Sigma, Taufkirchen, Germany) and goat anti-rabbit (Biorad, Munich, Germany). When required, cells were starved by total serum withdrawal for up to 100 h and treated with growth factors as indicated in the figure legends.
Sequencing and mutational analysis
Primers for PCR amplification of cDNA or genomic DNA samples (and sequencing) were designed using Primer3 program (http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_ www.cgi) and synthesized by Proligo (Sigma-Aldrich, Singapore, Singapore). PCR reactions were performed as previously described (Ruhe et al., 2007) . Direct sequencing was carried out on a 96-well capillary automated sequencing apparatus (ABI 3730XL, Foster City, CA, USA). Sequence traces were analysed to identify potential genomic alterations using the Mutation Surveyor (SoftGenetics, State College, PA, USA). The coding sequence of FGFR4 was aligned to NCBI reference sequence (NM_002011).
Quantitative real-time (RT)-PCR Quantitative RT-PCR was performed using Applied Biosystems 7300 (ABI) with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as control. Primers used include FGFR1 forward: CTCGGGACAGACTGGTCTTAGG, reverse: CGT CCGACTTCAACATCTTCAC; FGFR2 forward: GCTCCAG AAGCCCTGTTTGA, reverse: AGGGCGAGCCCCCTAAA; FGFR3 forward: GACCGAGGACAACGTGATGA, reverse: GTGAGTGTAGACTCGGTCAAACAAG; FGFR4 forward: CCCTCGAATAGGCACAGTTACC, reverse: AGCGGAACT TGACGGTGTTC; GAPDH forward: ATGTTCGTCATGGG TGTGAA, reverse: TGTGGTCATGAGTCCTTCCA. The samples were prepared in triplicates with 4 ml of prediluted cDNA each. Data were obtained as average CT values, and normalized against control as DCT. Expression changes in FGFR2-4 transcripts were compared with FGFR1 by expressing them as fold change using 2C T (difference between the DCT of FGFR1 and FGFR2-4).
Cell culture, plasmids and transfection The cell lines MDA-MB-453, MDA-MB361 and HEK293 were obtained from ATCC (American Type Culture Collection, Manassas, VA, USA) and cultivated according to the suppliers' instructions, except for MDA-MB453 cells, which were maintained in RPMI medium, supplemented with 10% fetal calf serum (FCS) and glutamine (Gibco/Invitrogen, Karlsruhe, Germany). pcDNA3 vectors containing human FGFR4-encoding cDNA have been described previously (Bange et al., 2002) . Other mutations were constructed by site-directed mutagenesis using Quick Change Kit (Stratagene, La Jolla, CA, USA). HEK293 cell lines stably expressing FGFR4 WT and FGFR4 Y367C mutation were generated by transfection with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions and selected with G418 for 2 weeks.
Cell lysis, immunoprecipitation and immunoblotting
Cell cultures were washed with PBS and incubated at 4 1C with lysis buffer (50 mM HEPES/NaOH, pH 7.5, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 10% glycerol and 1% Triton X-100) supplemented with phosphatase and protease inhibitors (10 mM sodium pyrophosphate, 1 mM phenylmethylsulphonyl fluoride, 2 mM sodium orthovanadate, 10 mg/ml aprotinin). Cellular debris was removed by centrifugation. Protein concentration measurements were performed using the Micro-BCA-Protein-Assay Kit from Pierce (Bonn, Germany). For immunoprecipitations, whole-cell lysates were combined with the respective antibodies and 30 ml of protein Aor G-sepharose slurry (GE Healthcare, Mu¨nchen, Germany). The samples were incubated for 3 h on a rotating wheel at 4 1C. The precipitates were washed three times with HNTG buffer (20 mM HEPES/NaOH, pH 7.5, 150 mM NaCl, 10% glycerol, and 0.1% Triton X-100 and 10 mM sodium pyrophosphate) suspended in 3 Â SDS sample buffer, boiled for 3 min and subjected to SDS-PAGE. For western blot analysis, proteins were transferred to nitrocellulose membranes and incubated with the appropriate antibodies. Signals were developed through an enhanced chemiluminescence detection system (ECL, Perkin-Elmer, Wellesley, MA, USA). Before re-probing, membranes were stripped with 65 mM Tris-HCl pH 6.8 buffer containing 2% SDS at 50 1C for 1 h.
RNA interference
Transfection of four distinct siRNA duplex sequences for targeting endogenous FGFR4 and one scrambled control (Dharmacon, Chicago, IL, USA) was carried out using Lipofectamine 2000 (Invitrogen) and 0.84 mg of siRNA duplexes per six-well plate as described previously (Elbashir et al., 2002) . Transfected cells were assayed on the indicated time points. Efficiency of silencing was determined by immunoblot assay of FGFR4 proteins. Sequences of siRNA used are siRNA-12: 5 0 -CCUCGAAU AGGCACAGUUA-3 0 ; siRNA-13: 5 0 -AUAACUACCUGCU AGAUGC-3 0 ; siRNA-14: 5 0 -GCACGAGGCUCCAUGAU GC-3 0 ; and siRNA-15: 5 0 -GAUUACAGGUGACUCCUUG-3 0 .
Proliferation and viability assay Cells (200 000) were seeded in six-well plates and counted at the indicated time points (up to 96 h) with a coulter counter.
To measure cell viability, Cell Titer-Glo assay (Promega, Madison, WI, USA), was performed on cells cultured on 96-well plates and assayed according to the manufacturer's instructions. Luminescence was detected on SpectraMax M5 (Molecular Devices, Sunnyvale, CA, USA).
In vitro wound closure assay The assay was performed as described previously, with some modifications (Fishman et al., 2001) . In brief, confluent monolayers of stably infected HEK293 cells were 'wounded' with a uniform scratch. Cells were allowed to migrate into the area of clearance for 24 h. Wound closure was monitored by using a Zeiss microscope (Oberkochen, Germany). Migrated cells were counted at two separate fields in each of the three treatment replicates and expressed as a percentage of wound closure as compared with the initial scratch.
Focus formation assay NIH3T3 cells (1 million cells each) were transfected with pcDNA3 vector, FGFR4 WT, FGFR4 Y367C or SRC oncogene using the Amaxa Nucleofactor program (Lonza, Walkersville, MD, USA) and seeded onto 6-cm dishes and maintained in culture for 21 days. Vector containing green fluorescent protein was used to determine the efficiency of transfection. Cells were then fixed with ice-cold methanol and stained with 0.5% crystal violet solution. After extensive washing with water, the dishes were air dried overnight for subsequent scanning.
